Ming‐Dauh Wang
Bayer (United States)(US)
Publications by Year
Research Areas
Statistical Methods in Clinical Trials, Lipoproteins and Cardiovascular Health, Health Systems, Economic Evaluations, Quality of Life, Statistical Methods and Inference, Computational Drug Discovery Methods
Most-Cited Works
- → Bayesian predictive approach to interim monitoring in clinical trials(2005)130 cited
- → Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study(2016)76 cited
- → Potent and Selective PPAR-α Agonist LY518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic Syndrome(2008)42 cited
- → Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults(2014)35 cited
- → Sample Size Reestimation by Bayesian Prediction(2007)28 cited
- → CYP‐mediated drug–drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome(2015)12 cited
- → An evaluation of the trimmed mean approach in clinical trials with dropout(2018)11 cited
- → Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors(2015)10 cited
- → SAFETY AND EFFICACY OF LY3015014, A NEW MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) WITH AN INHERENTLY LONGER DURATION OF ACTION, IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: A RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING, PHASE 2 STUDY(2015)8 cited
- → Abstract 12252: Effects of the Cholesteryl Ester Transfer Protein Inhibitor, Evacetrapib, Administered as Monotherapy or in Combination With Statins on Cholesterol Efflux and HDL Particles in Patients With Dyslipidemia(2014)8 cited